Niagen Bioscience

NAGE · NASDAQ

$2.51+$0.01 (+0.40%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $2.50

NAGE analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 8 analysts

Average $12.32 (+391.0% upside)

Low: $8.59
Now: $2.51
High: $23.10

Upgrades and downgrades

The latest rating actions, newest first

NAGE analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	May 11, 2026	Maintains	Buy	$12.00 → $11.00	43%
Canaccord Genuity	May 5, 2026	Maintains	Buy	$13.00 → $10.00	42%
Canaccord Genuity	Mar 31, 2026	Maintains	Buy	$13.00	42%
Canaccord Genuity	Mar 5, 2026	Maintains	Buy	$14.00 → $13.00	42%
Canaccord Genuity	Nov 5, 2025	Maintains	Buy	$16.00 → $14.00	42%

The case for and against

Updated Sep 16, 2026

Bull case

Niagen Bioscience is a company with strong financials and a promising outlook, supported by its innovative NAD+-boosting solutions and leadership in the healthy-aging research space. However, delays in product launches or slower-than-expected sales growth could pose risks to the company's growth trajectory. Nonetheless, with multiple potential growth drivers including the introduction of a pen-like autoinjector and recent partnerships and expansions, along with a strong intellectual property portfolio and increasing consumer interest in health and wellness, the company presents an attractive investment opportunity for potential investors.

Bear case

Niagen Bioscience is heavily reliant on its newly launched Niagen Plus telehealth platform, which we believe may face challenges in gaining traction and widespread acceptance. The company's bypass of traditional commercial channels and move towards direct-to-patient sales through telehealth may result in limited market reach and higher operational costs. Additionally, the company's potential value in treating rare diseases may not be realized until 2030, and there is a low likelihood of success in this area, making it a risky investment.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.